The share issue in OssDsign AB (publ) before listing on Nasdaq First North oversubscribed

On May 2, 2019, the Board of Directors of OssDsign AB (publ) (“OssDsign” or the “Company”) resolved, with the support of the authorization from the Annual General Meeting on April 24, 2019, on a share issue of up to 5,500,000 shares (the “Offer”) and to apply for admission to trading of the Company’s shares on Nasdaq First North. Expected first day of trading is May 24, 2019. There has been a strong interest for participating in the Offer and the Offer was subscribed to approximately 117 percent. Through the Offer, the Company will raise approximately SEK 151.3m before transaction costs. Provided that the over-allotment option of an additional 825,000 shares is fully exercised, the Company will raise an additional SEK 22.7m before transaction costs. OssDsign is provided around 2,000 new shareholders through the Offer.

The last day to subscribe for shares in the Offer was May 17, 2019. The Offer will increase the number of shares in the Company from 12,233,168 shares to 17,733,168 shares, corresponding to a dilution of 31 percent. If also the over-allotment option is fully exercised, the total number of shares will increase by an additional 825,000 shares to a total of 18,558,168 shares and the total dilution effect will amount to 34 percent. The subscription price was SEK 27.50 per share. The Offer was covered up to approximately 74 percent by subscription commitments from a number of institutional and private investors, including the Company’s two largest shareholders as well as the Company’s Chairman Simon Cartmell and Board Member Anders Qvarnström.

”It is very gratifying to see that it has been a great interest for OssDsign and that we have succeeded in attracting both reputable institutional owners and achieving a wide distribution of shares in our offer. The completed share issue and the forthcoming listing on Nasdaq First North will enable us to pursue our strategy and implement the planned market investments required to achieve strong growth as well as sustainable and increasing profitability.”, says Anders Lundqvist, CEO of OssDsign.

Allotment
Decision on allotment of subscribed shares has been made in accordance with the principles stated in the prospectus that was published on May 2, 2019. Notification of allotment of shares is made by distribution of a contract note, which is expected to take place around May 21, 2019. Payment for allotted shares shall be made in accordance with instructions on the contract note and the settlement day is May 23, 2019. Only those who have been allotted shares will be notified.

Advisors
Erik Penser Bank is the financial advisor in connection with the Offer. SV Ventures has acted as Co-Advisor to the Company in strategic matters related to the Offer and Setterwalls Advokatbyrå is the legal advisor in connection with the Offer.

Certified Adviser
The Company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Phone: +46 73 206 98 08, email: al@ossdsign.com 

About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

Important information
Publication or distribution of this press release may, in some jurisdictions, be subject to statutory restrictions, and persons in jurisdictions where this press release has been published or distributed should inform themselves and follow such legal restrictions. The information in this press release may not be forwarded, reproduced or displayed in a manner contrary to such restrictions.

Copies of this press release are not made and may not be distributed or transmitted, in whole or in part, directly or indirectly, to Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States or to any other jurisdiction in which the distribution of this press release would be illegal. The information in this press release shall not constitute an offer to sell shares or an invitation to an offer to purchase shares, nor shall any sale of the securities referred to herein take place in any jurisdiction where such an offer, an invitation to purchase or sale, would require the production of further prospectuses or other offer documents or would not be lawful without registration or applicable exemption from registration under the securities laws of such jurisdiction. This press release does not constitute, or form part of, an offer or an invitation to an offer to buy or subscribe for securities in the United States. Securities referred to herein has not and will not be registered in accordance with the US Securities Act of 1933 in its latest wording "Securities Act" and may not be offered or sold in the United States without registration in accordance with the Securities Act or any related exception. Securities referred to herein are not offered to the public in the United States.

Tags:

About Us

OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

Subscribe

Documents & Links